Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:03 PM
Ignite Modification Date:
2025-12-24 @ 4:03 PM
NCT ID:
NCT05627466
Eligibility Criteria:
Key Inclusion Criteria:
* Individuals with confirmation of acute myeloid leukemia (AML) according to WHO 2016 classification who are refractory or relapsed, ineligible for all known drugs with proven efficacy, and ineligible for existing clinical studies; and the treating physician has assessed that the potential benefits of magrolimab outweigh the risks.
* Eastern Cooperative Oncology Group performance status score of 0 to 3.
* Treating physician plans to administer magrolimab in combination with azacitadine/venetoclax or magrolimab in combination with azacitadine alone, following the indication-specific combinations described in the protocol.
Key Exclusion Criteria:
* Known hypersensitivity to magrolimab, azacitidine, venetoclax, their metabolites, or formulation excipients, if applicable to planned treatment regimen.
* Prior treatment with cluster of differentiation (CD)47 or signal regulatory protein alpha (SIRPĪ±)-targeting agents.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05627466
Study Brief:
Protocol Section:
NCT05627466